JP2019512020A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512020A5
JP2019512020A5 JP2018561191A JP2018561191A JP2019512020A5 JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5 JP 2018561191 A JP2018561191 A JP 2018561191A JP 2018561191 A JP2018561191 A JP 2018561191A JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5
Authority
JP
Japan
Prior art keywords
vaccine
days
use according
inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018561191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/017445 external-priority patent/WO2017139628A1/en
Publication of JP2019512020A publication Critical patent/JP2019512020A/ja
Publication of JP2019512020A5 publication Critical patent/JP2019512020A5/ja
Priority to JP2022064122A priority Critical patent/JP2022088665A/ja
Ceased legal-status Critical Current

Links

JP2018561191A 2016-02-12 2017-02-10 がんの治療 Ceased JP2019512020A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022064122A JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US62/294,349 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US62/404,252 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022064122A Division JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Publications (2)

Publication Number Publication Date
JP2019512020A JP2019512020A (ja) 2019-05-09
JP2019512020A5 true JP2019512020A5 (enExample) 2020-03-26

Family

ID=59088211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561191A Ceased JP2019512020A (ja) 2016-02-12 2017-02-10 がんの治療
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Country Status (8)

Country Link
US (5) US11000578B2 (enExample)
EP (1) EP3413927A4 (enExample)
JP (2) JP2019512020A (enExample)
CN (1) CN108883203A (enExample)
AU (1) AU2017217940B2 (enExample)
CA (1) CA3013930C (enExample)
HK (1) HK1258319A1 (enExample)
WO (1) WO2017139628A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
WO2020097209A1 (en) * 2018-11-06 2020-05-14 Wisconsin Alumni Research Foundation Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
JP2022519328A (ja) * 2019-02-08 2022-03-22 マディソン ヴァクシーンズ インコーポレイテッド 癌の治療
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
WO2021108331A1 (en) * 2019-11-26 2021-06-03 The Regents Of The University Of California Combination therapy for head and neck cancer
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
WO2022009052A2 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20250057642A1 (en) 2021-12-23 2025-02-20 Universiteit Maastricht Immunoprotective Type Implantable Cell Delivery Device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7179797B2 (en) 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗b7−h1抗体を用いた癌及び感染性疾患の組合せ療法
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
US7635753B2 (en) 2007-02-19 2009-12-22 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
US7867483B2 (en) * 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011130742A2 (en) 2010-04-16 2011-10-20 Wisconsin Alumni Research Foundation Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
US8603485B2 (en) 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
CA2871711A1 (en) * 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
ES2716685T3 (es) * 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
KR20170052569A (ko) * 2014-07-18 2017-05-12 어드박시스, 인크. 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
CA2965530A1 (en) 2014-11-07 2016-05-12 Wisconsin Alumni Research Foundation Targeting dna vaccines to b cells
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
WO2017139755A1 (en) 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Similar Documents

Publication Publication Date Title
JP2019512020A5 (enExample)
JP7712970B2 (ja) ホットスポットを利用した新生抗原の特定
Pandya et al. The future of cancer immunotherapy: DNA vaccines leading the way
Schirrmacher From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment
JP7480064B2 (ja) パンアレルモデルによる新生抗原の特定方法
Molodtsov et al. Tissue resident CD8 memory T cell responses in cancer and autoimmunity
Zhu et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions?
Zhang et al. Personalized cancer vaccines: Targeting the cancer mutanome
JP2021176866A (ja) 共通ネオ抗原
TWI893039B (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
JP2017524337A5 (enExample)
JP2012515213A5 (enExample)
Medler et al. Defining immunogenic and radioimmunogenic tumors
Liu et al. Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective
Mishchenko et al. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy
WO2017177207A1 (en) Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
JP2023516954A (ja) 遺伝子サンプリングにおける統計的バイアスの軽減
KR20210018321A (ko) 종양 특이적 신생항원 및 이를 사용하는 방법
CN106243213A (zh) 一种肿瘤相关抗原XAGE‑1b短肽及应用
Zhang et al. Age-related differences in molecular profiles for immune checkpoint blockade therapy
CN107864656A (zh) 重组分枝杆菌作为免疫治疗剂用于治疗癌症
US20180133270A1 (en) Recombinant oncolytic viruses and uses thereof
Fousteri et al. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure
Kato et al. RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer
Chen et al. Viral‐Directed Augmentation of Kupffer Cell Cross‐Presentation Provokes Antitumor Immunity Against Liver Metastasis